Laboratory technique to multiply a DNA sample for study
POPULARITY
Categories
55 episodes with pcr
63 episodes with pcr
26 episodes with pcr
24 episodes with pcr
24 episodes with pcr
18 episodes with pcr
18 episodes with pcr
31 episodes with pcr
16 episodes with pcr
37 episodes with pcr
12 episodes with pcr
49 episodes with pcr
18 episodes with pcr
10 episodes with pcr
9 episodes with pcr
27 episodes with pcr
14 episodes with pcr
8 episodes with pcr
19 episodes with pcr
16 episodes with pcr
9 episodes with pcr
8 episodes with pcr
10 episodes with pcr
8 episodes with pcr
12 episodes with pcr
21 episodes with pcr
12 episodes with pcr
16 episodes with pcr
21 episodes with pcr
15 episodes with pcr
10 episodes with pcr
20 episodes with pcr
20 episodes with pcr
20 episodes with pcr
13 episodes with pcr
14 episodes with pcr
12 episodes with pcr
13 episodes with pcr
10 episodes with pcr
5 episodes with pcr
18 episodes with pcr
8 episodes with pcr
10 episodes with pcr
8 episodes with pcr
6 episodes with pcr
8 episodes with pcr
10 episodes with pcr
10 episodes with pcr
8 episodes with pcr
9 episodes with pcr
4 episodes with pcr
5 episodes with pcr
13 episodes with pcr
20 episodes with pcr
7 episodes with pcr
4 episodes with pcr
8 episodes with pcr
7 episodes with pcr
4 episodes with pcr
8 episodes with pcr
7 episodes with pcr
9 episodes with pcr
10 episodes with pcr
8 episodes with pcr
13 episodes with pcr
6 episodes with pcr
7 episodes with pcr
18 episodes with pcr
5 episodes with pcr
10 episodes with pcr
8 episodes with pcr
13 episodes with pcr
8 episodes with pcr
7 episodes with pcr
12 episodes with pcr
12 episodes with pcr
7 episodes with pcr
4 episodes with pcr
7 episodes with pcr
3 episodes with pcr
12 episodes with pcr
5 episodes with pcr
7 episodes with pcr
7 episodes with pcr
5 episodes with pcr
4 episodes with pcr
11 episodes with pcr
5 episodes with pcr
6 episodes with pcr
3 episodes with pcr
5 episodes with pcr
5 episodes with pcr
7 episodes with pcr
10 episodes with pcr
9 episodes with pcr
5 episodes with pcr
6 episodes with pcr
3 episodes with pcr
6 episodes with pcr
6 episodes with pcr
4 episodes with pcr
6 episodes with pcr
3 episodes with pcr
4 episodes with pcr
5 episodes with pcr
7 episodes with pcr
4 episodes with pcr
6 episodes with pcr
7 episodes with pcr
6 episodes with pcr
6 episodes with pcr
6 episodes with pcr
5 episodes with pcr
4 episodes with pcr
3 episodes with pcr
13 episodes with pcr
5 episodes with pcr
5 episodes with pcr
3 episodes with pcr
9 episodes with pcr
4 episodes with pcr
5 episodes with pcr
3 episodes with pcr
4 episodes with pcr
3 episodes with pcr
7 episodes with pcr
2 episodes with pcr
8 episodes with pcr
6 episodes with pcr
12 episodes with pcr
3 episodes with pcr
5 episodes with pcr
5 episodes with pcr
2 episodes with pcr
13 episodes with pcr
4 episodes with pcr
3 episodes with pcr
4 episodes with pcr
8 episodes with pcr
4 episodes with pcr
5 episodes with pcr
5 episodes with pcr
4 episodes with pcr
2 episodes with pcr
4 episodes with pcr
2 episodes with pcr
3 episodes with pcr
5 episodes with pcr
6 episodes with pcr
4 episodes with pcr
5 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
7 episodes with pcr
7 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
2 episodes with pcr
4 episodes with pcr
9 episodes with pcr
5441 風とあそぶ：） 20251106THU 今日のCOVID-19・・・1817回目予防は治療に勝る!!!・・・■COVID Incubation Period: Facts You Should Knowhttps://www.health.com/covid-incubation-period-11704405■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5438 風とあそぶ：） 20251105WED 今日のCOVID-19・・・1816回目起きている事は起きている・・・■COVID Incubation Period: Facts You Should Knowhttps://www.health.com/covid-incubation-period-11704405■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
Following a fruitful European Society of Medical Oncology (ESMO) Congress 2025 for gastrointestinal malignancies, CancerNetwork® organized an X Spaces discussion hosted by 3 experts. They were Nicholas J. Hornstein, MD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health; Timothy Brown, MD, an assistant professor in the Department of Internal Medicine and the associate program director of the Hematology & Oncology Fellowship at UT Southwestern Medical Center; and Udhayvir S. Grewal, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Each doctor focused on a specific disease type, highlighting the most important abstracts in colorectal cancer, pancreatic neuroendocrine tumors (NETs), and upper gastrointestinal cancers. The Phase 3 MATTERHORN Trial (NCT04592913) Results from MATTERHORN demonstrated that adding durvalumab (Imfinzi) to 5-fluorouracil, leucovorin (folinic acid), oxaliplatin, and docetaxel (FLOT) improved overall survival (OS) compared with FLOT plus placebo in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, regardless of pathological status.1 In the intention-to-treat population, the median OS was not reached in either arm, and the hazard ratio (HR) was 0.78 (95% CI, 0.63-0.96; P = .021). Notably, the improvement was observed regardless of PD-L1 status; in patients with PD-L1–positive disease, the HR was 0.79 (95% CI, 0.63-0.99), and in patients with PD-L1–negative disease, the HR was 0.79 (95% CI, 0.41-1.50). “This, I believe, will seal durvalumab plus FLOT as the standard of care for resectable [gastric/GEJ] cancers,” said Brown. The Observational ASPEN Study (NCT03084770) The ASPEN study showed that active surveillance was a safe approach for patients with low-grade, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NETs) fewer than 2 centimeters in size.2 Of the 1000 patients enrolled in the trial, 20 patients died, of whom 18 underwent active surveillance and 2 underwent surgery. Nineteen of the deaths were unrelated to pancreatic NETs; 1 death in the surgery arm was related to a pancreatic NET. After surgery, 5 patients had disease relapse or progression. With a median follow-up of 42 months (IQR, 25-60), the OS analysis showed a P value of 0.530. “This really settles the debate on whether or not to surgically operate on patients with a [pancreatic NET] size of [fewer] than 2 centimeters and shows that active surveillance is a safe option for these patients with pancreatic NETs [fewer] than 2 centimeters in size and non-functional NETs,” said Grewal. Data From the Phase 2/3 FOxTROT (NCT00647530) and Phase 2 NICHE-2 (NCT03026140) Trials Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) achieved a clinically meaningful and statistically significant improvement in long-term outcomes, including responses and survival, compared with chemotherapy strategies in patients with mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) locally advanced colon cancer.3 In NICHE-2, neoadjuvant nivolumab plus ipilimumab achieved a 3-year disease-free survival (DFS) rate of 100% compared with 80% (95% CI, 73%-85%) with all chemotherapy strategies in FOxTROT (P
5435 風とあそぶ：） 20251104TUE 今日のCOVID-19・・・1815回目寒暖差拡大・・・■COVID Incubation Period: Facts You Should Knowhttps://www.health.com/covid-incubation-period-11704405■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5432 風とあそぶ：） 20251103MON 今日のCOVID-19・・・1814回目連休・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
The JournalFeed podcast for the week of Oct 27-31, 2025.These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Monday's Spoon Feed:Early fluid resuscitation in sepsis shows a U-shaped relationship between fluid amount and mortality; 30 mL/kg within 3 hours improves survival, supporting current Surviving Sepsis Campaign guidance.Friday's Spoon Feed:Azelastine nasal spray used three times daily for 56 days significantly reduced PCR-confirmed SARS-CoV-2 infections versus placebo.
5429 風とあそぶ：） 20251102SUN 今日のCOVID-19・・・1813回目脅威への備え・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5426 風とあそぶ：） 20251101SAT 今日のCOVID-19・・・1812回目出来る事を・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
Dr. Landon Pryor shares his transformation from a traditional plastic surgeon who believed implants were safe to becoming a dedicated explant specialist who refuses to place devices anymore. After watching patient after patient experience "miraculous recoveries" following explant surgery in 2018, he realized he couldn't justify putting foreign objects into women's bodies, even with informed consent. Both surgeons dive deep into why standard culture testing misses biofilm infections, how textured devices create a "Rocky Mountains" effect of inflammation, and why every single implant they've removed shows chronic inflammatory response. This isn't just another medical discussion, it's two surgeons following the evidence wherever it leads, even when it means challenging everything the medical establishment still teaches today. IN THIS EPISODE WE'LL: * Discover why standard infection testing from 1950 completely misses bacterial biofilms living on breast implants * Transform your understanding of why implants were moved behind the muscle (hint: it wasn't for your benefit) * Break through the myths about fat transfer and why it's been unfairly demonized in reconstruction * Learn why PCR testing reveals what traditional cultures hide about implant contamination CHECK OUT THESE EPISODES: Episode 125: Dr. Daniel Pompa on Biotoxins, Detox Strategies, and Finding BII Relief: https://podcasts.apple.com/us/podcast/episode-125-dr-daniel-pompa-on-biotoxins-detox-strategies/id1678143554?i=1000717790234 Episode 137: Environmental Toxins Are Messing With Your Body, Here's How to Fight Back with Dr. Aly Cohen: https://podcasts.apple.com/us/podcast/episode-137-environmental-toxins-are-messing-with-your/id1678143554?i=1000730936483 Links and Resources Dr. Pryor's website: https://www.biicentersofexcellence.com/ Check out Dr. Whitfield's research on biofilms: https://www.mdpi.com/2076-2607/12/9/1830 Let's Connect Podcast: https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554 Spotify: https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667 TikTok: https://www.tiktok.com/@drrobertwhitfield?_t=8oQyjO25X5i&_r=1 IG: https://www.instagram.com/breastimplantillnessexpert/ FB: https://www.facebook.com/DrRobertWhitfield Linkedin: https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/ X: https://x.com/rob_whitfieldmd Read this article - https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness Shop: https://drrobssolutions.com SHARP: https://www.harp.health NVISN Labs - https://nvisnlabs.com/ Get access to Dr. Rob's Favorite Products below: Danger Coffee - Use our link for mold free coffee - https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg JASPR Air Purifier - Use code DRROB for the Jaspr Air Purifier - https://jaspr.co/ Echo Water - Get high quality water with our code DRROB10 - https://echowater.com/ BallancerPro - Use code DRROBVIP for the world's leader in lymphatic drainage technology - https://ballancerpro.com Ultrahuman - Use code WHITFIELD10 for the most accurate wearable - https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield
5423 風とあそぶ：） 20251031FRI 今日のCOVID-19・・・1811回目世界中で各種感染症の波・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5420 風とあそぶ：） 20251030THU 今日のCOVID-19・・・1810回目リスクと隣あわせ・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5417 風とあそぶ：） 20251029WED 今日のCOVID-19・・・1809回目懸念・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
AABP executive Director Dr. Fred Gingrich reviews a paper published in The Bovine Practitioner with two of the authors. Joining today are Dr. Greg Habing, professor in the Department of Preventive Medicine at The Ohio State University College of Veterinary Medicine, and Dr. Emily Nogay, clinical assistant professor at The Ohio State University Large Animal Ambulatory Services. Salmonella Dublin is a host-adapted and zoonotic pathogen affecting many dairy farms. It can be associated with high morbidity and mortality and is often multi-drug resistant which elevates its importance to dairy farmers and veterinarians. Surveillance and diagnostics are an important aspect of managing diseases in our herds. Nogay reviews available diagnostic tests and the advantages and disadvantages of each one. The ELISA test has a sensitivity of 65%, but is used to screen herds for the disease. The objective of this study was to determine if the four U.S. commercially licensed Salmonella vaccines would result in a positive Salmonella Dublin ELISA test result. We walk through the results of the paper and discuss some of the findings, including the impact of the vaccines on the serum ELISA results and some potential reasons for the ELISA results after vaccination. Habing discusses future opportunities for research on this disease, including the need for better diagnostic tests, including a PCR test to screen herds. AABP's peer-reviewed journal, The Bovine Practitioner, publishes original research studies, reviews, case series, and case reports intended to provide clinically relevant research to private practicing veterinarians. It is an open access journal and there are no publication fees for submitting authors. Read more about the journal at this link. The effect of Salmonella vaccination on Salmonella Dublin blood enzyme-linked immunosorbent assay results. Bov Pract. 2025;59(2), 53-60. https://doi.org/10.21423/bpj20259266
Fresh off a successful collaboration with Walmart to get potato packaging with PCR content onto store shelves, Kevin Kelly of Emerald Packaging talks about the challenges of getting sustainable flexible packaging into the market.
5414 風とあそぶ：） 20251028TUE 今日のCOVID-19・・・1808回目新たな波・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
C dans l'air l'invité du 25 octobre 2025 avec François Houdecek, historien à la Fondation Napoléon, spécialiste de la Grande armée et de ses soldatsDans une étude publiée dans la revue Current Biology le 24 octobre 2025, des scientifiques de l'Institut Pasteur font part de leurs résultats d'analyses génétiques sur des dents d'anciens soldats de la Grande guerre lors de la retraite de Russie en 1812. Ils ont mis au jour l'existence de deux nouvelles maladies présente à cette période : la fièvre paratyphoïde et la fièvre récurrente. Une "découverte majeure", d'autant que les méthodes employées sont "très novatrices", comme le précise Rémi Barbieri, post-doctorant dans l'Unité de Paléogénomique Microbienne de l'Institut Pasteur pendant l'étude, et premier auteur de celle-ci. En 2006, le typhus et la fièvre des tranchées avaient été identifiées via des tests PCR effectués sur des restes de 40 soldats du charnier de Vilius, ne permettant de trouver que les maladies recherchées. Mais cette fois-ci, de l'ADN a été extrait des dents de 13 soldats napoléoniens."On pense que 500 000 à 600 000 soldats étaient partis et que la moitié sont morts de maladies, de faim, de froid ou de fatigue et que la majorité des morts le seraient à cause de maladies infectieuses", précise Rémi Barbieri. Le chercheur ajoute : "Pour l'instant on en a identifié quatre, mais on pense qu'on pourrait en trouver beaucoup plus." Le manque d'hygiène a été particulièrement propice à la prolifération de poux, puces et autres insectes, générateurs de maladies.François Houdecek est historien à la Fondation Napoléon, spécialiste de la Grande armée et de ses soldats. Il reviendra sur la découverte par des chercheurs de l'Institut Pasteur de deux nouvelles maladies présentes lors de la retraite de Russie en 1812. Il est l'auteur de "Vivre la Grande Armée. Être soldat au temps de Napoléon" aux CNRS Editions et il vient de publier avec le Service Historique de la Défense « Les guerres Napoléoniennes dans l'Histoire » aux éditions Pierre de Taillac.
5411 風とあそぶ：） 20251027SUN 今日のCOVID-19・・・1807回目都合によるリスクの拡大・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5408 風とあそぶ：） 20251026SUN 今日のCOVID-19・・・1806回目財政格差・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5405 風とあそぶ：） 20251025SAT 今日のCOVID-19・・・1805回目寒暖差・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5402 風とあそぶ：） 20251024FRI 今日のCOVID-19・・・1804回目世界的に油断出来ず・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
Dr. Michael Schwartz is a man of many talents. As a former Police Officer he has trained departments and agencies how to read body language. As a research doctor, he saved thousands of lives during Covid by using PCR testing the way it was designed, to cut through the propaganda and deliver real patient care. He is author of three books which can all be found on Amazon. #BardsFM #OvercomingTyranny #Faith Bards Nation Health Store: www.bardsnationhealth.com BardsFM CAP, Celebrating 50 Million Downloads: https://ambitiousfaith.net Morning Intro Music Provided by Brian Kahanek: www.briankahanek.com MYPillow promo code: BARDS Go to https://www.mypillow.com/bards and use the promo code BARDS or... Call 1-800-975-2939. White Oak Pastures Grassfed Meats, Get $20 off any order $150 or more. Promo Code BARDS: www.whiteoakpastures.com/BARDS Windblown Media 20% Discount with promo code BARDS: windblownmedia.com Founders Bible 20% discount code: BARDS >>> TheFoundersBible.com Mission Darkness Faraday Bags and RF Shielding. Promo code BARDS: Click here EMPShield protect your vehicles and home. Promo code BARDS: Click here EMF Solutions to keep your home safe: https://www.emfsol.com/?aff=bards Treadlite Broadforks...best garden tool EVER. Promo code BARDS: TreadliteBroadforks.com No Knot Today Natural Skin Products: NoKnotToday.com Health, Nutrition and Detox Consulting: HealthIsLocal.com Destination Real Food Book on Amazon: click here Images In Bloom Soaps and Things: ImagesInBloom.com Angeline Design: AngelineDesign.com DONATE: Click here Mailing Address: Xpedition Cafe, LLC Attn. Scott Kesterson 591 E Central Ave, #740 Sutherlin, OR 97479
5399 風とあそぶ：） 20251023THU 今日のCOVID-19・・・1803回目鳥インフル・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5396 風とあそぶ：） 20251022WED 今日のCOVID-19・・・1802回目出来る事を・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
Muy buena semana para todos.En este episodio revisaremos la segunda parte sobre la ventilación en el parocardáorespiratorio (PCR). Un tema algo controversial, al menos para mí, de acuerdo a lo que revisaremos en este capítulo. Espero que te sea de mucha utilidad y que sirva para tener un punto de conversación sobre nuestra practica diaria. En este episodio hablamos de: Ventilación asincrónicaFrecuencia Ventilatoria en PCRVolumen Tidal Ideal Ventilación Mecánica invasica y PCRTe comparto el link de esta publicación. No olvides suscribirte a nuestro podcast y compartir este episodio con quien necesite conocer esta información. Saludos y buena SemanaDavid Larrondo FonsecaLinks: Zoll: www.zoll.comArticulo:https://www.resuscitationjournal.com/article/S0300-9572(24)00260-0/fulltext
5393 風とあそぶ：） 20251021TUE 今日のCOVID-19・・・1801回目医療格差・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5390 風とあそぶ：） 20251020MON 今日のCOVID-19・・・1800回目危機・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5387 風とあそぶ：） 20251019SUN 今日のCOVID-19・・・1799回目リスク回避・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
5384 風とあそぶ：） 20251018SAT 今日のCOVID-19・・・1798回目常態化にあらがう・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
This week's episode of the Glossy Beauty Podcast introduces a three-week series dedicated to beauty packaging. Despite daily interacting with beauty products — including face wash, body wash, lipstick or shampoo — consumers rarely spend time thinking about the countless decisions that go into a brand's packaging. From sustainability (Are refills offered? Is the plastic PCR?) to color (think: the pull of millennial pink) to font, every packaging element is carefully considered. As our first guest in the series, FIT Professor Sebba Alqetrani, said, “The first thing the consumer sees, touches and interacts with is the package. [It] is your first opportunity to have a first impression.” Over the next two weeks, we will explore just why packaging is so important and what factors can make it impactful, whether it has to do with a product's efficacy, branding or deeper emotional resonance. But first, a look at some of this week's headlines including the launch of Ulta Beauty's UB Marketplace, a curated third-party marketplace that will allow the mega beauty retailer to integrate many new brands into its existing e-commerce site; Sephora's growth, bolstered in part by Rhode's buzzy launch, according to LVMH's recent earnings; and The Body Shop's return to U.S. sales , launching online through a direct-to-consumer site and Amazon.
Functionally Enlightened - Better ways to heal from chronic pain and illness
Lyme disease shouldn't be a guessing game.In this episode, Nicole Bell—MIT/Duke engineer, author of What Lurks in the Woods, and CEO of Galaxy Diagnostics—shares how her husband's undiagnosed Lyme and co-infections (Bartonella, Babesia) led to a tragic outcome… and why that drove her mission to change the standard of care for tick-borne illness.We break down:-Why antibody tests miss stealth infections -How direct detection (PCR, digital PCR) + sample enrichment improve sensitivity-Smart strategies to test co-infections (e.g., urine antigen for Borrelia, blood enrichment for Bartonella)-Practical tips (timing, pre-test movement/sauna, re-testing windows)-Advocacy: finding clinicians, navigating “normal” labs, and pushing for answersResources mentioned:Galaxy Diagnostics: galexydx.com (education center + testing info)Center for Lyme Action “State of Lyme Disease Research”Pathways for non-licensed practitioners (via Mosaic Diagnostics, Evexia, Rupa) – coming online soonIf you or a loved one is stuck with “inconclusive” results, this conversation offers a roadmap—grounded in science and born from lived experience.
5381 風とあそぶ：） 20251017FRI 今日のCOVID-19・・・1797回目すぐ、うごけるように・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
By now you have probably heard about the sunscreen testing scandal. Earlier this year in June, CHOICE tested a bunch of sunscreen products in the Australian market, and many came back well under their marketed SPF. The one that really caught everyone's attention was from Ultraviolet, with a claimed SPF of 50+, results came back at 4. What came next was some of the most bizarre behaviour I think I've ever observed in the beauty industry. First with some of the brand responses, then to the dynamics on social media. Things evolved quickly, where now the TGA has stepped in, a bunch of sunscreens have been recalled, and it looks like there may have been some testing fraud. To help us understand this mess, I brought together an expert roundtable with the people I thought were best positioned to do the topic justice - in conversation with Brian Ecclefield, industry testing expert who also has firsthand experience with PCR, the lab behind the scandal. Dr. Michelle Wong from Labmuffin Beauty Science, science content creator who's pretty much the sunscreen science queen of the interwebs in my books. And finally, Hannah English, sunscreen and science content creator, also coming with the brand founder POV. Michelle and Hannah collectively did some of the best scicomm on this story on social media as it all unfolded, they were my steadfast voices of reason. If you work in beauty, this conversation probably should be a must listen! Interested in supporting the podcast? Please share, subscribe and write a review! If it's accessible, we also have a Patreon which you can find at patreon.com/theecowell
5378 風とあそぶ：） 20251016THU 今日のCOVID-19・・・1796回目自治体の長・・・■PCR nowhttps://pcrnow.jp■コロナ早期診断・治療｜新型コロナは終わっていない｜ 塩野義製薬https://bit.ly/4kLQEV6■検証なきコロナ禍 ～いまこそ「下水サーベイランス」（北島正章さん・兪炳匡さん）【山岡純一郎のニッポンの崖っぷち】20250716https://youtu.be/jqPogTrB56Y?si=aJkT66VcHjKcCGpz■BREAKING! The New SARS-CoV-2 Variant, NB.1.8.1 is the Most Dangerous So Far Poses a Major Threat!https://www.thailandmedical.news/news/breaking-the-new-sars-cov-2-variant-nb-1-8-1-is-the-most-dangerous-so-far-and-poses-a-major-threat■札幌市下水サーベイランスhttps://www.city.sapporo.jp/gesui/surveillance.html■新型コロナ・季節性インフルエンザの流行状況速報値の活用例監修モデルナhttps://moderna-epi-report.jp/■全員が安全になるまで、誰も安全ではないNobody is safe until everybody is safe■◇■ 予防は治療に勝る!!! ■◇■●WHOコロナ後遺症の方のためのガイドラインhttp://bit.ly/3kteZFv 日本語●職場復帰に関するガイドラインー英国産業衛生学会http://bit.ly/3ZWmipo 日本語■Flowflex フロウフレックス 抗原検査キットhttps://amzn.to/46LQ3wY■株式会社 CLEAIRhttps://cleair-w.com/■ゲノムに聞け 最先端のウイルスとワクチンの科学https://amzn.to/42pt7DH気合・気愛で555!!!アラキ：）KOJI ARAKI Art WorksCopyright KOJI ARAKI Art Works All Rights Reserved
No Check-up Semanal de hoje, Ronaldo Gismondi traz os principais destaques em Terapia Intensiva: o uso de hidrocortisona em cirróticos com choque séptico, a relação entre pressão arterial média e desfechos neurológicos após PCR, o papel do ácido tranexâmico na hemorragia digestiva, o impacto dos antibióticos inalados na pneumonia associada à ventilação e as melhores práticas para intubação traqueal em emergências.
JCO PO author Dr. Asaf Maoz at Dana-Farber Cancer Institute shares insights into article, “Causes of Death Among Individuals with Lynch Syndrome in the Immunotherapy Era.” Host Dr. Rafeh Naqash and Dr. Maoz discuss the causes of death in individuals with LS and the evolving role of immunotherapy. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor Medicine, at the OU Health Stephenson Cancer Center. Today, I'm super thrilled to be joined by Dr. Asaf Maoz, Medical Oncologist at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and faculty at the Harvard Medical School, and also lead author on the JCO Precision Oncology article entitled "Causes of Death Among Individuals with Lynch Syndrome in the Immunotherapy Era." This publication will be a concurrent publication with an oral presentation at the annual CGA meeting. At the time of this recording, our guest's disclosures will be linked in the transcript. Asaf, I'm excited to welcome you on this podcast. Thank you for joining us today. Dr. Asaf Maoz: Thank you so much for highlighting our paper. Dr. Rafeh Naqash: Absolutely. And I was just talking to you that we met several years back when you were a trainee, and it looks like you've worked a lot in this field now, and it's very exciting to see that you consider JCOPO as a relevant home for some of your work. And the topic that you have published on is of significant interest to trainees from a precision medicine standpoint, to oncologists in general, covers a lot of aspects of immunotherapy. So, I'm really excited to talk to you about all of this. Dr. Asaf Maoz: Me too, me too. And yeah, I think JCOPO has great content in the area of cancer genetics and has done a lot to disseminate the knowledge in that area. Dr. Rafeh Naqash: Wonderful. So, let's get started and start off, given that we have hosts of different kinds of individuals who listen to this podcast, especially when driving from home to work or back, for the sake of making everything simple, can we start by asking you what is Lynch syndrome? How is it diagnosed? What are some of the main things to consider when you're trying to talk an individual where you suspect Lynch syndrome? Dr. Asaf Maoz: Lynch syndrome is an inherited predisposition to cancer, and it is common. So, we used to think that, or there's a general notion in the medical community that it is a rare condition, but we actually know now from multiple studies, including studies that look at the general population and do genetic testing regardless of any clinical phenotype, that Lynch syndrome is found in about 1 in 300 people in the general population. If you think about it in the United States, that means that there are over a million people living with Lynch syndrome in the United States. Unfortunately, most individuals with Lynch syndrome don't know they have Lynch syndrome at the current time, and that's where a lot of the efforts in the community are being made to help detect more individuals who have Lynch syndrome. Lynch syndrome is caused by pathogenic germline variants in mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, or as a result of pathogenic variants in EPCAM that cause silencing of the MSH2 gene. Dr. Rafeh Naqash: Excellent. Thank you for that explanation. Now, one of the other things I also realized, similar to BRCA germline mutations, where you require a second hit for individuals with Lynch syndrome to have mismatch repair deficient cancers, you also require a second hit to have that second hit result in an MSI-high cancer. Could you help us understand the difference of these two concepts where generally Lynch syndrome is thought of to be cancers that are mismatch repair deficient, but that's not necessarily true for all cases as we see in your paper. Can you tease this out for us a little bit more? Dr. Asaf Maoz: Of course, of course. So, the germline defect is in one of the mismatch repair genes, and these genes are responsible for DNA mismatch repair, as their name implies. Now, in a normal cell, we think that one working copy is generally enough to maintain the mismatch repair machinery intact. What happens in tumors, as you alluded to, is that there is a second hit in the same mismatch repair gene that has the pathogenic germline variant, and that causes the mismatch repair machinery not to work anymore. And so what happens is that there is formation of mutations in the cancer cell that are not present in other cells in the body. And we know that there are specific types of mutations that are associated with defects in mismatch repair mechanisms, and those are associated a lot of times with frameshift mutations. And we have termed them ‘microsatellites'. So there are areas in the genome that have repeats, for example, you know, if you have AAAA or GAGA, and those areas are particularly susceptible to mutations when the mismatch repair machinery is not working. And so we can measure that with DNA microsatellite instability testing. But we can also get a sense of whether the mismatch repair machinery is functioning by looking at protein expression on the surface of cancer cells and by doing immunohistochemistry. More recently, we're also able to infer whether the mismatch repair machinery is working by doing next-generation sequencing and looking at many, many microsatellites and whether they have this DNA instability in the microsatellites. Dr. Rafeh Naqash: Excellent explanation. As a segue to what you just mentioned, and this reminds me of some work that one of my good friends, collaborators, Amin Nassar, whom you also know, I believe, had done a year and a half back, was published in Cancer Cell as a brief report, I believe, where the concept was that when you look at these mismatch repair deficient cancers, there is a difference between NGS testing, IHC testing, and maybe to some extent, PCR testing, where you can have discordances. Have you seen that in your clinical experience? What are some of your thoughts there? And if a trainee were to ask, what would be the gold standard to test individuals where you suspect mismatch repair deficient-related Lynch syndrome cancers? How would you test those individuals? Dr. Asaf Maoz: We do sometimes see discordance, you know, from large series, the concordance rate is very high, and in most series it's over 95%. And so from a practical perspective, if we're thinking about the recommendation to screen all colorectal cancer and all endometrial cancer for mismatch repair deficiency, I think either PCR-based testing or immunohistochemistry is acceptable because the concordance rate is very high. There are rare cases where it is not concordant, doing multiple of the tests makes sense at that time. If you think about the difference between the tests, the immunohistochemistry looks at protein expression, which is a surrogate for whether there is mismatch repair deficiency or not, right? Because ultimately, the mismatch repair deficiency is manifested in the mutations. So if the PCR does not show microsatellite instability and now NGS does not show microsatellite instability, the IHC may be a false positive. At the end of the day, the functional analysis of whether there are actually unstable microsatellites either by PCR or by NGS is what I would consider more informative. But IHC again is an excellent test and concordant with those results in over 95% of cases. Now there is also an issue of sampling. It's possible that there's heterogeneity within the tumor. We published a case in JCOPO about heterogeneity of the mismatch repair status, and that was both by immunohistochemistry, but also by PCR. So there are some caveats and interpreting these tests does require some expertise, and I'm always happy to chat with trainees or whoever has an interesting or challenging case. Dr. Rafeh Naqash: Thanks again for that very easy to understand explanation. Now going to management strategies, could you elaborate a little bit upon the neo-adjuvant data currently, or the metastatic data which I think more people are familiar with for immunotherapy in individuals with MSI-high cancers? Dr. Asaf Maoz: Yeah, that's an excellent question and obviously a very broad topic. Individuals with Lynch syndrome typically develop tumors that are mismatch repair deficient or microsatellite unstable. And we have seen over the last 15 years or so that these tumors, because they have a lot of mutations and because these mutations are very immunogenic, we have seen that they respond very well to immunotherapy. And this has been shown across disease sites and has been shown across disease settings. And for that reason, immunotherapy was approved for MSI-high or mismatch repair deficient cancer regardless of the anatomic site. It was the first tissue-agnostic approval by the FDA in 2017. And so there are exciting studies both in the metastatic setting where we see individuals who respond to immunotherapy for many years, and one could wonder whether their cancer is going to come back or not. And also in the earlier setting, for example, the Cercek et al. study in the New England Journal from Sloan Kettering, where they showed that neoadjuvant immunotherapy can cause durable responses for rectal cancer that is mismatch repair deficient. And in that series, the patients did not require surgery or radiation, which is standard of care for rectal cancer otherwise. And there's also exciting data in the adjuvant space, as was presented in ASCO by Dr. Sinicrope, the ATOMIC study, and many more efforts to bring immunotherapy into the treatment landscape for individuals with MSI-high cancer, including individuals with Lynch syndrome. Dr. Rafeh Naqash: A lot of activity, especially in the neo-adjuvant and adjuvant space over the last two years or so. Now going to the actual reason why we are here is your study. Could you tell us why you looked at this idea of patients who had Lynch syndrome and died, and the reasons for their death? What was the thought that triggered this project? Dr. Asaf Maoz: As we were talking about, we now know that immunotherapy really has changed the treatment landscape for individuals with Lynch syndrome, and that most cancers that individuals with Lynch syndrome do have this mismatch repair deficiency. But we also know that individuals with Lynch syndrome can develop tumors that do not have mismatch repair deficiency, and we call them mismatch repair proficient or microsatellite stable. And there was a series from Memorial Sloan Kettering showing that in colorectal cancer, about 10% of the tumors that individuals with Lynch syndrome developed did not have mismatch repair deficiency. In addition to that, we anecdotally saw that some of our patients with Lynch syndrome died of causes that were not mismatch repair deficient tumors. We wanted to see how that has changed since immunotherapy was approved in a tissue-agnostic manner, meaning that we could look at this regardless of where the cancer started, because we would anticipate that if the tumor was mismatch repair deficient, the patient would be able to access immunotherapy as standard of care. Dr. Rafeh Naqash: Thank you. And then you looked at different aspects of correlations with regards to individuals that had an MSI-high cancer with Lynch syndrome or an MSS cancer with Lynch syndrome. Could you elaborate on some of the important findings that you identified as well as some of the unusual findings that perhaps we did not know about, even though the sample size is limited, but what were some of the unique things that you did identify through this project? Dr. Asaf Maoz: The first question was what cause is leading to death in individuals with Lynch syndrome? And we had 54 patients that we identified that had died since the approval of immunotherapy in 2017, 44 of which died of cancer-related causes. And when we looked at cancer-related causes of death, we wanted to know how many of those were due to mismatch repair deficient tumors versus mismatch repair proficient tumors or MS-stable tumors. And we found, somewhat surprisingly, that 43% of patients in our cohort actually died of tumors that were microsatellite stable or mismatch repair proficient, meaning of tumors that are not typically associated with Lynch syndrome. This is not entirely surprising as a cause of death because we know that immunotherapy does not typically work for tumors that are microsatellite stable. And so in the metastatic setting, there are much less cases of durable remissions with treatment. But it was helpful to have that figure as an important benchmark. There are previous studies about causes of death in Lynch syndrome, and particularly from the Prospective Lynch Syndrome Database in Europe. Those have provided really important information about cause of death by cancer site, but they typically don't have mismatch repair status and are more difficult to interpret in that regard. They also don't include a large number of individuals who have PMS2 Lynch syndrome, which is the most common, but least penetrant form of Lynch syndrome. Dr. Rafeh Naqash: As far as the subtype of pathogenic germline variants is concerned, did you notice anything unusual? And I've always had this question, and you may know more about this data, is: In the bigger context of immunotherapy, does the type of the pathogenic germline variant for Lynch syndrome associated MSI-high cancers, does that impact or have an association with the kind of outcomes, how soon a cancer progresses or how many exceptional responders perhaps with MSI-high cancers actually have a certain specific pathogenic germline variant? Dr. Asaf Maoz: That's an excellent question, and certainly we need more data in that space. We know that the type of germline mutation, or the gene in which there is a germline pathogenic variant, determines to a large degree the cancer risk, right? So we know that individuals who have germline pathogenic variants in MLH1 or MSH2 have a much higher colorectal cancer risk than, for example, PMS2. We know that for PMS2, the risks are more limited to colorectal and endometrial, and may be lower risk of other cancers. We also know that, you know, the spectrum of disease may change based on the pathogenic germline variants. For example, individuals who have MSH2 associated Lynch syndrome have more risk of additional cancers in other organs like the urinary tract and other less common Lynch-associated tumors. The question about response to therapy is one where we have much less information. There are studies that are trying to assess this, but I don't think the answer is there yet. Some of the non-clinical data looks at how many mutations there are based on the pathogenic variant and what the nature of those mutations are, whether they're more frameshift or others. But I think we still need more clinical data to understand whether the response to immunotherapy differs. It's also complicated by the fact that the immunotherapy landscape is changing, especially in the metastatic setting, now with the approval of combination ipilimumab and nivolumab for first-line treatment of colorectal cancer that is microsatellite unstable. But in our study, we did find that, as you would expect, there is an enrichment in MS-stable cancers among those with PMS2 Lynch syndrome. Again, our denominator is those who died, right? So this is not the best way to look at the question whether this is overall true, that is more addressed by the study that Sloan Kettering published. But we do see, as we would anticipate, that there are more microsatellite stable cancers among those with PMS2 Lynch syndrome that died. Dr. Rafeh Naqash: A lot to uncover there for sure. This study and perhaps some of the other work that you're doing is slowly advancing our understanding of some of these concepts. So I'd like to shift gears to a couple of provocative questions that I generally like to ask. The first is, in your opinion, and you may or may not have data to back this up, which is okay, and that's why we're having a conversation about it. In your opinion, do you think the type or the quality of the neoantigen is different based on the pathogenic germline variant and a Lynch syndrome associated MSI-high cancer? Dr. Asaf Maoz: I think there are some data out there that, you know, I can't cite off the top of my mind, but there are some data out there that suggest that that may be the case. I think the key question is the quality, right? I think that whether these differences that are found on a molecular level also translate to a clinical difference in response is something that is unknown at this moment. Some people hypothesize that if the tumor has less neoantigens, there's less of a response to immunotherapy. But I think we really need to be careful before making those assertions on a clinical level. I do think it's a really important question that needs to be answered, among others because, you know, in the colorectal space, for example, where we have both the option of doing ipilimumab with nivolumab and the option of doing pembrolizumab, we don't really know which patients need the CTLA-4 blockade versus which patients can receive PD-1 blockade alone and avoid the potential excess toxicity of the CTLA-4 blockade. There are a lot of interesting questions there that still need to be answered. And of course, individuals with Lynch syndrome are just a fraction of those individuals who have MSI-high cancer. So there's also the question about whether non-Lynch syndrome associated MSI-high cancer responds differently to immunotherapy than Lynch syndrome associated MSI-high cancer. A lot of very interesting questions in the field for sure. Dr. Rafeh Naqash: Absolutely. My second question is more about trying to understand the role of ctDNA, MRD monitoring in individuals with Lynch syndrome. If somebody has a germline, you know, Lynch syndrome MSI-high cancer, when you do a tumor-informed ctDNA assessment, what do you capture generally there? Because, and this question stems from a discussion I've had with somebody regarding EGFR lung cancer, since I treat individuals with lung cancer, and the concept generally is that even if the tissue showed EGFR, but for MRD monitoring, when you do a barcoded sequence of different tumor specific mutations, it's not actually the EGFR that they track in the blood when they do ctDNA assessment. But from a Lynch syndrome standpoint, if you have a germline, right, which is the first hit, and then you have the somatic in the tumor, which is the second hit, are you aware or have you tried to look into this where what is exactly being followed if one had to follow MRD in a Lynch syndrome MSI-high colorectal cancer? Dr. Asaf Maoz: I think a lot of the MRD assays are proprietary, and so we don't receive information about what the mutations that are being tracked are. In general, the idea is to track mutations that we would not expect to disappear as part of resistant mechanisms. We want these to be truncal mutations. We want these to be mutations in which resistance is not expected to result in reversion mutations. But what specifically is being tracked is something that I don't know because these assays, the tumor-informed ones, are proprietary, and we don't get the results regarding specific mutations. When it's circulating tumor DNA that is not necessarily tumor-informed, we do get those results, but that is less so about the specific selection of mutations. Dr. Rafeh Naqash: Thank you for clarifying that question to some extent, of course, as you said, we don't know a lot, and we don't know what we don't know. That's the most important thing that I've learned in the process of understanding precision medicine and genomics, and it's a very fast-paced evolving field. Last question related to your project, what is the next step? Are you planning any next steps as a bigger multicenter study or validation of some sort? Dr. Asaf Maoz: There are two big questions that this study raises. One, is this true across multiple other sites, right? Because this is a single center study, and we really need additional centers to look at their data and validate whether they are also seeing that a substantial portion of deaths in individuals with Lynch syndrome are attributable to mismatch repair proficient cancer. The other question is whether we can look at specifically MSI-high cancer versus MS-stable cancer and understand what the mortality rate for each of those are. From a clinical perspective, it's important to counsel individuals with Lynch syndrome about general cancer screening outside of mismatch repair deficient tumors and to understand that there is also a risk of mismatch repair proficient tumors and that treatment for those tumors would be different. There's a lot of work to be done in the future. Another major area of need is to see whether tumors that are microsatellite stable can be sensitized to immunotherapy, and that is beyond the Lynch syndrome field, but that is something that certainly would benefit these individuals with Lynch syndrome who develop mismatch repair proficient cancer. Dr. Rafeh Naqash: That's very interesting to hear, and we'll look forward to seeing some of those developments shape in the next few years. Now, I'd like to spend a minute, minute and a half on you specifically as a researcher, clinician, scientist. Could you briefly highlight - because I remember meeting you several years back as a trainee, with your interest in genomics, computational research - could you briefly tell us what led you to hereditary cancer syndromes based on your research and work? What are some of the things that you learned along the way that other early career investigators can perhaps take lessons from? Dr. Asaf Maoz: Big questions there, thanks for asking. I got interested in the field of hereditary cancer syndromes when I came to the United States and started doing lab research in Stephen Gruber's lab at the time at USC. He's now at City of Hope. And my interest was originally looking at immunotherapy and immunology, but I went to the case conferences where we were learning about individuals with hereditary cancer, and those were kind of earlier days where we were still trying to figure out how to test and what the implications for these individuals would be. And through fellowship, I was also very interested in that, and I did my senior fellowship years with Dr. Yurgelun here at Dana-Farber, who is the director of the Lynch Syndrome Center. And I I think it's the combination between being able to treat individuals based on precision medicine and what the germline mutation is, but also the ability to prevent cancer and to develop strategies to intercept cancer early that is really appealing to me in this field. It's also a great field to be in because it's a small field. If you come to the CGA-IGC meeting, you'll be able to interact with everyone. Everyone is super collaborative, super nice, and I really recommend it to trainees. The CGA-IGC annual meeting is really a great opportunity to learn more and experience some of the advancement specifically in the GI hereditary space. Lessons for trainees. I think there are a lot of lessons that I could think about, but I think finding strong and supportive mentors is one of the things that has helped me most. I think that just having close relationship with your mentor, having frequent discussions and honest discussions about what is feasible, what is going to make a difference for your patients and your research and what you want to focus on is really important. And so I think if I had to choose one thing, I would say choose a mentor that you trust, that you feel you have a good relationship with, and that has the availability to support you. Dr. Rafeh Naqash: Thank you so much for those insightful comments, and thank you for sharing with us your journey, your project, and some of your interesting thoughts on this concept of hereditary cancers. Hopefully, we'll see more of this work being published in JCOPO through your lab or work from others. Dr. Asaf Maoz: Thank you so much. I appreciate the opportunity to be here. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
In this second half of our discussion with Dr. Erin McCreary and Dr. Hannah Creager, we dive deeper into how microbiology and antimicrobial stewardship teams collaborate to improve patient outcomes. They unpack how to prioritize breakpoint updates, the pros and cons of cascade reporting, and what nudges can do to guide better prescribing. Then we explore a powerful example of collaboration—the transition from MRSA agar to PCR across hospitals—and what it taught both teams about communication, resource sharing, and patient safety. Finally, Erin and Hannah reflect on lessons learned, first steps for building collaboration, and even share their favorite microbes (spoiler: both picked viruses!).
Professor Norman Fenton is a mathematician and risk expert who rose to prominence during COVID for cutting through flawed statistics and exposing how data was used and misused to shape policy. “There was never any justification for the lockdowns in the first place, and the whole COVID hysteria was based on massively exaggerated case and mortality numbers created by flawed definitions, easily manipulated data, and inaccurate mass testing of healthy people.” In this episode, Dr. Brian, Dr. Tro, and Prof. Norman talk about… (00:00) Intro (01:52) Governmental misinterpretation of Covid data and the resulting Covid policies (12:05) False Covid case numbers (17:40) The complicity of the scientific, academic, and physician communities in Covid vaccine policies and lockdown policies (25:12) How flawed and manipulated the PCR test is (29:02) The true devestation of the lockdowns (32:55) Prof. Norman's fellow colleagues who joined him in challenging the Covid narrative (35:29) Early warning signs that the mRNA Covid vaccines were not going to be safe or effective (46:55) How the all-cause mortality data has changed since the initial release of the vaccines (48:30) Vaccine risk/benefit for healthy, fit people (49:47) Early red flags about the whole Covid situation and governmental responses (51:16) How much money people made off of the Covid situation (54:28) Prof. Norman's personal experience fighting the Covid machine (01:01:39) Israel's Covid mortality data and suppression of valid data from respected researchers (01:08:50) Why vaccine related deaths are probably exaggerated For more information, please see the links below. Thank you for listening! Links: Please consider supporting us on Patreon: https://www.lowcarbmd.com/ Prof. Norman Fenton: Website: https://www.normanfenton.com X: https://x.com/profnfenton Fighting Goliath (book): https://wherearethenumbers.substack.com/p/our-book-out-now-fighting-goliath YouTube: https://www.youtube.com/channel/UCygtzcy5WGNluXjhA1cuT9w Dr. Brian Lenzkes: Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author Dr. Tro Kalayjian: Website: https://www.doctortro.com/ Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/ Toward Health App Join a growing community of individuals who are improving their metabolic health; together. Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more. Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888 Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://doctortro.com/community/
Rebecca Culshaw Smith's Substack, “The Real AIDS Epidemic,” highlights core criticisms of mainstream HIV/AIDS theory, medical testing, pharmaceutical practices, and challenges to scientific orthodoxy. Based on her popular posts, interviews, and thematic content, these are 20 of the most important ideas advanced on her platform: 1. Questioning the existence of HIV as a unique virus, arguing that classic virological isolation (Koch's postulates) has not been fulfilled. 2. Highlighting the non-specificity and cross-reactivity of HIV antibody tests, leading to potential misdiagnosis. 3. Criticism of “viral load” PCR tests for not detecting whole pathogens but only RNA fragments. 4. Noting the shifting criteria for HIV test positivity over time, calling diagnostic standards into question. 5. Documenting long-term “non-progressors” and “elite controllers” who remain healthy without antiretroviral therapy. 6. Raising awareness of AIDS-defining illnesses in HIV-negative individuals and questioning causality. 7. Arguing that hazard from AIDS medications (e.g., AZT, Truvada, Prep) may outweigh their benefits, especially due to their toxicity and inconsistent trial results. 8. Critique of the marketing and deployment of pre-exposure prophylaxis (Prep), calling it a pharmaceutical “scandal” targeting people not at significant risk. 9.Exploring how COVID-19 public health narratives mirror what she views as deception and fear tactics from the AIDS era. 10. Disputing the epidemiological narrative that AIDS is globally caused by a single infectious agent, and highlighting massive regional/demographic inconsistencies. 11. Exposing groupthink, censorship, and reputational shaming used against scientists questioning the HIV/AIDS paradigm. 12. Emphasizing failures of antiretroviral therapy in preventing disease progression for many patients. 13.. Explaining the statistical and mathematical problems in foundational HIV/AIDS research and the “shaky foundation” of guiding studies. 14. Arguing that AIDS-defining diseases may often reflect toxicity, malnutrition, or existing comorbidities, not a distinct viral syndrome. 15. Linking historical and social factors (such as drug use, pharmaceutical incentives) to the creation and persistence of the HIV/AIDS establishment. 16. Alerting readers to issues of false positive antenatal screening and broader concerns about mass diagnostic testing in medicine. 17. Suggesting that “virus-like particles” in the body are misidentified as pathogens, not proof of HIV's existence. 18. Forecasting that advances in AI and technology may help overturn scientific “consensus” by increasing transparency and debate. 19 Publicly refuting hit pieces and attempts to “cancel” her work as ideological suppression, not science. 20.Advocating for a return to fundamental scientific rigor and genuine skepticism in medical research, especially around virology and public health narratives. These topics synthesize her core objections to HIV/AIDS orthodoxy and frame her Substack as a point of dissent and critique against modern medical paradigms and their social consequences.
Bartonella is a genus of Gram-negative bacteria. It is the only genus in the family Bartonellaceae. Facultative intracellular parasites, Bartonella species can infect healthy people, but are considered especially important as opportunistic pathogens. Bartonella species are transmitted by vectors such as fleas, sand flies, and mosquitoes. At least eight Bartonella species or subspecies are known to infect humans. Bartonella henselae is the organism responsible for cat scratch disease. History Bartonella species have been infecting humans for thousands of years, as demonstrated by Bartonella quintana DNA in a 4000-year-old tooth. The genus is named for Alberto Leonardo Barton Thompson (1871–October 26, 1950), a Peruvian scientist. Infection cycle Though some studies have found "no definitive evidence of transmission by a tick to a vertebrate host," Bartonella species are well-known to be transmissible to both animals and humans through various other vectors, such as fleas, lice, and sand flies. Bartonella bacteria are associated with cat-scratch disease, but a study in 2010 concluded, "Clinicians should be aware that ... a history of an animal scratch or bite is not necessary for disease transmission." All current Bartonella species identified in canines are human pathogens. SUMMARY Bartonella is a type of bacteria that can make people very sick. There are three main kinds that cause most of the infections: B. henselae, B. quintana, and B. bacilliformis. Some of these bacteria are found all over the world (like B. henselae), but others only live in certain places (like B. bacilliformis). People can catch Bartonella in different ways: B. henselae – usually from a cat scratch or bite. B. quintana – spread by body lice. B. bacilliformis – spread by sand flies. Once the bacteria get into the body, they infect red blood cells and cause the blood vessels to grow abnormally. This can lead to symptoms like long-lasting fever, swollen lymph nodes, and enlarged liver or spleen. Doctors figure out if someone has Bartonella using lab tests. They might grow the bacteria in a culture, look for antibodies in the blood (serology), or look at tissues under a microscope. Special tests called PCR can find Bartonella DNA in blood or tissue samples, including heart valves. Treatment usually involves antibiotics, but the exact medicine depends on which type of Bartonella you have and how sick you are. In some cases, like with cat-scratch disease, a doctor may need to use a needle to drain swollen lymph nodes.
Vidcast: https://www.instagram.com/p/DOwe9yfDnI2/Azelastine nasal spray, marketed as Astepro but also available as a generic, can reduce your chances of developing a CoVid infection by a factor of 3 and cut your chances of developing a common cold by a factor of 3.5. German researchers at Saarland University recently published their double-blind, placebo-controlled study of 450 participants in the JAMA Internal Medicine Journal.Half the subjects received azelastine 0.1% nasal spray three times a day for 56 days. The control subjects used a similarly-appearing but inactive nasal spray. Respiratory infections were confirmed using PCR analyses. The results showed that only 2.2% of the azelestine sprayers developed CoVid compared with 6.7% of controls. Only 1.8% of azelestine sprayers developed rhinovirus infections compared with 6.3% of controls.Generic azelastine spray is a prescription medication. Astepro Spray, the same medication, is available over-the-counter. If you think you might benefit, give it a try.https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2838335#azelastine #astepro #allergy #CoVid #rhinovirus #commoncold
O que antes parecia simples — AINE + colchicina e, na dúvida, corticoide — agora tem um novo protagonista: os anti-IL1.Neste episódio do DozeCast, Mateus Prata, William Batah e o especialista Dr. Vinícius Correia trazem todas as novidades sobre Pericardita e explicam de forma clara e prática:Por que o corticoide deixou de ser primeira escolha na recorrente.Os novos critérios diagnósticos.Quando encaminhar para os Centros de Excelência em Doenças Pericárdicas.E, principalmente: o que você deve mudar amanhã na sua conduta.Minutagem:(03:32) - Epidemiologia da Pericardite Aguda(05:18) - Quem é o paciente mais suscetível a Pericardite Aguda?(06:38) - As principais causas de Pericardite Aguda(10:30) - A importância do novo consenso de Pericardite Aguda(12:18) - Novos critérios diagnósticos de Pericardite Aguda(24:09) - ECO e Ressonância, para quem indicar na Pericardite Aguda?(26:03) - Exames laboratoriais que devem ser solicitados na Pericardite Aguda(28:04) - Quem é o paciente que deve ser internado por Pericardite Aguda?(32:10) - A importância da PCR na Pericardite Aguda(35:16) - Tratamento clínico da Pericardite Aguda(45:15) - Quando devo dar corticoide no tratamento da Pericardite Aguda?(47:40) - Quais pacientes merecem transferência para um centro especializado?(50:40) - Pericardiotomia, quando deve ser indicada?_____________________________Assine agora! Revisões didáticas de Cardiologia, semanalmente na DozeNews PRIME: a maneira mais leve e rápida de se manter atualizado(a), através do link dozeporoito.com/prime
Dr. Kathleen Horst, Dr. Rachel Jimenez, and Dr. Yara Abdou discuss the updated guideline from ASTRO, ASCO, and SSO on postmastectomy radiation therapy. They share new and updated recommendations on topics including PMRT after upfront surgery, PMRT after neoadjuvant systemic therapy, dose and fractionation schedules, and delivery techniques. They comment on the importance of a multidisciplinary approach and providing personalized care based on individual patient characteristics. Finally, they review ongoing research that may impact these evidence-based guidelines in the future. Read the full guideline, “Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline” at www.asco.org/breast-cancer-guidelines" TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01747 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Kathleen Horst, expert panel chair from Stanford University; Dr. Rachel Jimenez, expert panel vice chair from Massachusetts General Hospital; and Dr. Yara Abdou, ASCO representative from the University of North Carolina, authors on "Postmastectomy Radiation Therapy: An American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology Clinical Practice Guideline." Thank you for being here today, Dr. Horst, Dr. Jimenez, and Dr. Abdou. Dr. Kathleen Horst: Thank you for having us. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Horst, Dr. Jimenez, and Dr. Abdou who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Then to dive into the content that we are here today to talk about, Dr. Horst, could you start us off by describing what prompted the update for this joint guideline between ASTRO, ASCO, and SSO, and what is the scope of this 2025 guideline on postmastectomy radiation therapy? Dr. Kathleen Horst: Thank you. This joint guideline was last updated in 2016. Over the past decade, the treatment of breast cancer has evolved substantially. Newer systemic therapy regimens have increasingly personalized treatment based on tumor biology, and local therapy management has explored both the de-escalation of axillary surgery and more abbreviated courses of radiation therapy. Given these advances, it was important to revisit the role of postmastectomy radiotherapy in this modern era of breast cancer therapy. This updated guideline addresses four key questions, including postmastectomy radiation therapy after upfront surgery as well as after neoadjuvant systemic therapy. It also reviews the evolving role of various dose and fractionation schedules and optimal treatment techniques and dose constraints. Brittany Harvey: Excellent. I appreciate that background, Dr. Horst. So then, next, Dr. Jimenez, I would like to review the recommendations of this guideline across those four key questions that Dr. Horst just mentioned. So first, what does the panel recommend for PMRT for patients who received initial treatment with mastectomy? Dr. Rachel Jimenez: The panel provided pretty strong consensus that patients with positive lymph nodes or patients with large tumors involving the skin or the chest wall should receive postmastectomy radiation. However, the panel also recognized that the omission of postmastectomy radiation may be appropriate for select patients who have positive lymph nodes and have an axillary lymph node dissection if they have a low nodal burden and other favorable clinical or pathologic features. For patients without lymph node involvement at the time of surgery and no involvement of the skin or chest wall, postmastectomy radiation was not advised by the panel. Brittany Harvey: Understood. It is helpful to understand those recommendations for that patient population. Following that, Dr. Abdou, what are the key recommendations for PMRT for patients who received neoadjuvant systemic therapy before mastectomy? Dr. Yara Abdou: When we think about PMRT after neoadjuvant treatment, the key point is that the initial stage of presentation still matters a lot. So for example, if a patient comes in with more advanced disease, say a large primary tumor, like a clinical T4, or more extensive nodal disease, like an N2 or N3 disease, those patients should get PMRT, no matter how well they respond to neoadjuvant therapy, because we know it reduces the risk of recurrence and that has been shown pretty consistently. On the other hand, if there are still positive lymph nodes after neoadjuvant treatment, basically residual nodal disease, PMRT is also strongly recommended because the risk of local-regional recurrence is much higher in that setting. The gray area is the group of patients who start with a lower burden of nodal disease, such as N1 disease, but then become node negative at surgery. For those patients, we tend to individualize the decision. So if the patient is young or has triple-negative disease, or if there is a lot of residual disease in the breast even though the nodes are cleared, then radiation is probably helpful. But if everything has melted away with pCR in both the breast and the nodes, then it may be safe to omit PMRT in those patients. For patients with smaller tumors and no nodal involvement to begin with, like a clinical T1-T2 N0, if they are still node negative after neoadjuvant treatment, then PMRT is generally not recommended because their baseline recurrence risk is low. And finally, if the margins are positive and cannot be re-excised, then PMRT is recommended after neoadjuvant therapy. Brittany Harvey: Yes, those distinctions are important for appropriate patient selection. So then, Dr. Horst, we have just reviewed the indications for PMRT, but for those patients who receive PMRT, what are the appropriate treatment volumes and dose fractionation regimens? Dr. Kathleen Horst: The guideline addresses coverage of the chest wall and regional nodes with a specific discussion of the data regarding internal mammary nodal irradiation, which has been an area of controversy over many years. The guideline also reviews the data exploring moderate hypofractionation, or shorter courses of radiation therapy. The task force recommends utilizing moderate hypofractionation for the majority of women requiring postmastectomy radiation, which is likely to have a large impact on clinical practice. This recommendation is based on the evolving data demonstrating that a 3-week course of radiotherapy after mastectomy provides similar oncologic outcomes and minimal toxicity for most patients compared to the standard 5-week treatment course. Brittany Harvey: Thank you for reviewing that set of recommendations as well. So then, Dr. Jimenez, to wrap us up on the key questions here, what delivery techniques are recommended for treating patients who receive PMRT? Dr. Rachel Jimenez: So this portion of the guideline is likely to be most helpful for radiation oncologists because it represents the most technical part of the guideline, but we do believe that it offers some important guidance that has, to this point, been lacking in the postmastectomy radiation setting. So first, the panel recommends that all patients should undergo 3-dimensional radiation planning using CAT scan based imaging, and this includes contouring. So contouring refers to the explicit identification, using a drawing interface on the CAT scan imaging, by the radiation oncologist to identify the areas that are targeted to receive radiation, as well as all of the nearby normal tissues that could receive unintended radiation exposure. And we also provide radiation oncologists in the guideline with suggestions about how much dose each target tissue should receive and what the dose limits should be for normal tissues. Additionally, we make some recommendations regarding the manner in which radiation is delivered. So for example, we advise that when conventional radiation methods are not sufficient for covering the areas of the body that are still at risk for cancer, or where too high of a dose of radiation would be anticipated to a normal part of the body, that providers employ a technique called intensity modulated radiation therapy, or IMRT. And if IMRT is going to be used, we also advise regular 3-dimensional imaging assessments of the patient's body relative to the treatment machine to ensure treatment fidelity. When the treatments are delivered, we further advise using a deep inspiration breath-hold technique, which lowers the exposure to the heart and to the lungs when there is concern for cardiopulmonary radiation exposure, and again, that image guidance be used along with real-time monitoring of the patient's anatomy when those techniques are employed. And then finally, we advise that patients receiving postmastectomy radiation utilize a bolus, or a synthetic substance placed on the patient's skin to enhance radiation dose to the superficial tissue, only when there is involvement of the skin with cancer or other high-risk features of the cancer, but not for every patient who receives postmastectomy radiation. Brittany Harvey: Understood. And then, yes, you just mentioned that section of the guideline is probably most helpful for radiation oncologists, but I think you can all comment on this next question. What should all clinicians, including radiation oncologists, surgical oncologists, medical oncologists, and other oncologic professionals, know as they implement all of these updated recommendations? Dr. Rachel Jimenez: So I think one of the things that is most important when we consider postmastectomy radiation and making recommendations is that this is a multidisciplinary panel and that we would expect and encourage our colleagues, as they interpret the guidelines, to employ a multidisciplinary approach when they are discussing each individual patient with their surgical and medical oncology colleagues, that there is no one size fits all. So these guidelines are intended to provide some general guidance around the most appropriate techniques and approaches and recommendations for the utilization of postmastectomy radiation, but that we recognize that all of these recommendations should be individualized for patients and also represent somewhat of a moving target as additional studies, both in the surgical and radiation oncology realm as well as in the systemic therapy realm, enter our milieu, we have to adjust those recommendations accordingly. Dr. Kathleen Horst: Yeah, I would agree, and I wanted to comment as a radiation oncologist, we recognize that local-regional considerations are intertwined with systemic therapy considerations. So as the data evolve, it is critical to have these ongoing updates in a cross-disciplinary manner to ensure optimal care for our patients. And as Dr. Jimenez mentioned, these multidisciplinary discussions are critical for all of us to continue to learn and understand the evolving recommendations across disciplines but also to individualize them according to individual patients. Dr. Yara Abdou: I could not agree more. I think from a medical oncology perspective, systemic therapy has gotten much better with adjuvant CDK4/6 inhibitors, T-DM1, capecitabine, and immune therapy. So these are all newer adjuvant therapies, so the baseline recurrence risks are lower than what they were in the trials that established PMRT. So the absolute benefit of radiation varies more now, so smaller for favorable biology but still relevant in aggressive subtypes or with residual disease. So it is definitely not a one-size-fits-all. Brittany Harvey: Yes, I think it is important that you have all highlighted that multidisciplinary approach and having individualized, patient-centric care. So then, expanding on that just a little bit, Dr. Abdou, how will these guideline recommendations affect patients with breast cancer? Dr. Yara Abdou: So basically, reiterating what we just talked about, these guidelines really move us towards personalized care. So for patients at higher risk, so those with larger tumors, multiple positive nodes, or residual nodal disease after neoadjuvant therapy, PMRT remains essential, consistently lowering local-regional recurrence and improving survival. But for patients at intermediate or lower risk, the recommendations support a more selective approach. So instead of a blanket rule, we now integrate tumor biology, response to systemic therapy, and individual patient factors to decide when PMRT adds meaningful benefit. So the impact for patients is really important because those at high risk continue to get the survival advantage of radiation while others can be spared the unnecessary treatment and side effects. So in short, we are aligning PMRT with modern systemic therapy and biology, making sure each patient receives the right treatment for their situation. Brittany Harvey: Absolutely. Individualizing treatment to every patient will make sure that everyone can achieve the best outcomes as possible. So then, Dr. Jimenez, to wrap us up, I believe Dr. Horst mentioned earlier that data continues to evolve in this field. So in your opinion, what are the outstanding questions regarding the use of PMRT and what are you looking to for the future of research in this space? Dr. Rachel Jimenez: So there are a number of randomized phase III clinical trials that are either in active accrual or that have reported but not yet published that are exploring further de-escalation of postmastectomy radiation and of axillary surgery. And so we do not yet have sufficient data to understand how those two pieces of information integrate with each other. So for example, if you have a patient who has a positive lymph node at the time of diagnosis and forgoes axillary surgery aside from a sentinel lymph node biopsy, we do not yet know that we can also safely forgo radiation entirely in that setting. So we expect that future studies are going to address these questions and understand when it is appropriate to simultaneously de-escalate surgery and radiation. Additionally, there is a number of trials that are looking at ways in which radiation could be omitted or shortened. So there is the RT CHARM trial, which has reported but not yet published, looking at a shorter course of radiation. And so we do make recommendations around that shorter course of radiation in this guideline, but we anticipate that the additional data from the RT CHARM study will provide further evidence in support of that. Additionally, there is a study called the TAILOR RT trial, which looks at forgoing postmastectomy radiation in patients who, to Dr. Abdou's point, have a favorable tumor biology and a low 21-gene recurrence score. And so we are going to anticipate the results from that study to help guide who can selectively forgo postmastectomy radiation when they fall into that favorable risk category. So there are a number of questions that I think will help flesh out this guideline. And as they publish, we will likely publish a focused update on that information to help provide context for our colleagues in the field and clarify some of these recommendations to suit the latest data. Brittany Harvey: Absolutely. We will look forward to those de-escalation trials and ongoing research in the field to build on the evidence and look for future updates to this guideline. So I want to thank you for your work to update these guidelines, and thank you for your time today, Dr. Horst, Dr. Jimenez, and Dr. Abdou. Dr. Rachel Jimenez: Thank you. Dr. Yara Abdou: Thank you. Dr. Kathleen Horst: Thank you. Brittany Harvey: And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Josh Sigurdson reports on the news of Covid Masks returning in western California as the CDC claims the west coast is at "high" of "very high" levels of so-called "Covid." This news comes as the UK plans the largest pandemic exercise in history (Exercise Pegasus) and Trump meets with Bill Gates. As we move into the autumn, this propaganda will only become louder. This year, the medical establishment and media are working overtime to fear monger about new pandemics, from the Bubonic Plague to Bird Flu, West Nile, Dengue, Chikungungya, Measles, Monkeypox and of course the infamous "SARS-CoV2." As per usual, there are no isolates, there is wastewater data which is heavily utilizing PCR tests which we already know are fraudulent when it comes to direct diagnosis. RFK Jr just sat through another hearing and insisted the covid injections will remain available for everyone. So far the only "justice" we've seen is a warning label for some. Meanwhile, 4 new mRNA Vaccines have been approved for children 6 months to 11 years old. While just 2 weeks ago, President Trump claimed he didn't get enough credit for Operation Warp Speed which disabled 36 million Americans and claimed that it was one of the greatest achievements in American history, claiming it was a "military procedure," he claimed just days later that he may have been mislead about the Vaccines. Wow... 5 and a half years later he thinks he may have been mislead. The fact that people are actually excited about this statement says a lot. How completely asleep does someone have to be to only slightly question the vaccines 5 and a half years later? This isn't an accomplishment, it's embarassing. Besides, he's demanding big pharma show proof of the vaccines' success, not failures. Don't get too hung up on this thinking this will be the end of big pharma. Emergency orders planned for the future "pandemics" are readily in place regardless of the president, but it's clear that Trump is either years behind and stupid OR an evil fraud pretending to start to question this NOW. That is for you to decide. Stay tuned for more from WAM! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# EVERYTHING SOLD OUT EXCEPT... Freeze dried chicken! 50% off with code WAM50! https://wambeef.com/ GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025
Lending his 25-year-old OLD soul voice, Canadian Liev Dalton, creator and host of his podcast and collective Beyond Terrain, shares his truth awakening story from his time in college. He observed firsthand the flaws of academia and science, from germ theory to PCR tests, and used the lockdown period to study, reflect and think critically. In our episode, he discusses the nature of law, fires, glyphosate spraying, whole terrain, synthetics, toxins and talks of dentistry by highlighting the studies of Canadian dentist, Westin A. Price. PS - he now has a master's in counseling psychology and runs a wilderness therapy practice. Closing with the "Just Be Practice," he encourages us to look outward so we can turn inward.Show Reference:Westin A. Price: https://www.westonaprice.org/#gsc.tab=0Connect with Liev:Website: https://BeyondTerrain.com/beyond-terrain-academy IG: https://www.instagram.com/beyond.terrain/?hl=en*Host Eden Koz is a soul realignment specialist utilizing psychological empathy, intuition, psychic ability, mediumship, meditation, mindset shift, Reiki, dimensional and galactic healing, to name a few. She also performs spiritual Co#id Vac+ Healing as well as remote & face-to-face sessions with individuals and groups. Contact info for Eden Koz / Just Be®, LLC:Website: EdenJustBe.com Socials: Insta, FB, FB (Just Be), TikTok, LinkedInJust Be~Spiritual BOOM Podcast can be found on Video directories: BitChute, Rumble, YouTube, Odysee, Grassroots Warrior Network. Audio directories: Apple Podcasts, Spotify, ...
ResourcesClick here to learn about United Ostomy Associates of America (UOAA) National Quality Ostomy Care Campaign, including the Ostomy and Continent Diversion Patient Bill of Rights,.Click here to view a list of patient resources that the WOCN Society has curated, including services, products, and publications. You can also bookmark and/or share the following web address with your colleagues and patients: IDeserveaWOCNurse.com.Click here to view and use the Peristomal Skin Assessment Guide for Clinicians and Consumers,. You can also bookmark and/or share the following web address with your colleagues and patients: psag.wocn.org.Click here to learn more about Janet's session at WOCNext® 2025, “I Have an Ostomy, Where can I go?: Challenges of Setting Up An Ostomy Clinic,.”The WOCN Society, in collaboration with the American Society of Colon and Rectal Surgeons (ASCRS) and the American Urological Association (AUA), developed the educational resources to assist clinicians in selecting an effective stoma site. Click here to review these resources.If you're a healthcare professional looking to deepen your knowledge of ostomy care, explore the joint WOCN and ASCRS Ostomy Care Management (OCM) Program—an evidence-based, online education designed to enhance care delivery and improve outcomes for individuals living with an ostomy. Click here to learn more.Journal of Wound, Ostomy, and Continence Nursing (JWOCN®) articles referenced in this episode:Bridging the Gap: Perceived Educational Needs in the Inpatient to Home Care Setting for the Person With a New OstomyLessons Learned About Peristomal Skin Complications Secondary Analysis of the ADVOCATE TrialOstomy and Continent Diversion Patient Bill of Rights Research Validation of Standards of CareOther articles referenced in this episode: The ostomy leak impact tool: development and validation of a new patient-reported tool to measure the burden of leakage in ostomy device usersImpact of stoma leakage in everyday life: data from the Ostomy Life Study 2019Factors impairing quality of life for people with an ostomy About the SpeakerJanet has enjoyed 40 years in WOC Nursing. Although her early nursing career focus was critical care as a certified critical care registered nurse she certified as a CWOCN in 1985. In 1996, she embarked in a private WOC practice, first as a partnership and then as sole proprietor practicing across the continuum with a focus on ostomy care coupled with a passion for patients attaining their desirable quality of life. Janet worked in outpatient ostomy clinics serving different populations and challenges... adding a bit of spice to her practice and recently retired from patient care.Janet lectures nationally and internationally, has published on Quality of Life of People Living with an Ostomy and co-authored both a home study course on Wound Management & Healing and an educational video on Common Perineal Skin Injuries, and. She participates in Ostomy and Incontinence Associated Dermatitis research and actively participates with WOCN and industry to move ostomy care forward. Her peers awarded her the PCR* ET Nurse of the Year Award in 1996, PCR* President's Award in 2000 and PCR* Professional Educational Award in 2004.*PCR stands for the Pacific Coast Region of the WOCN Society, what is now known as the Pacific Coast Chapter of the WOCN Society (or PCC for short). The WOCN Society has 11 chapters throughout the country that support WOCN members at a local level with resources, education, networking opportunities, social gatherings, timely information, and more. For additional information, please visit wocn.org/Chapters. Editing and post-production work for this episode was provided by The Podcast Consultant.
YEP…Its another episode of You Asked, We Answered! In this episode, we will look at the data to answer 2 questions that came into the show within the last 24 hrs: 1. Is oral or topical therapy best for first treatment of uncomplicated vulvovaginal candidiasis? (We have new data- AJOG, Sept 2025, to answer that), and 2. Is urine PCR testing for UTI diagnosis a “routine practice”? (We will look at 4 sources of information to answer that one). Listen in for details. 1. Gardella, Barbara et al. Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Single-day or multiple-day therapy? A network meta-analysis of randomized trials. American Journal of Obstetrics & Gynecology, Volume 233, Issue 3, 152 - 1612. Invited Commentary: JAMA Netw Open: Published Online: November 26, 20242024;7;(11):e2446711. doi:10.1001/jamanetworkopen.2024.467113. March 2025 (AAFP): Are the Advantages of Urine PCR Testing Worth the Higher Costs? https://www.aafp.org/pubs/afp/afp-community-blog/entry/are-the-advantages-of-urine-pcr-testing-worth-the-higher-costs.html4. July 2025: PALTmed: https://paltmed.org/news-media/paltmed-calls-providers-stop-using-routine-pcr-urine-tests-utis5. https://pathnostics.com/limitations-of-pcr-only/
Drs. Whitney Hartlage (@whithartlage11) and Sam Windham join Dr. Ryan Moenster to discuss updates in the diagnosis and management of community-acquire pneumonia. Hear from our guests on the role of rapid diagnostic tests such as multiplex PCR and urinary antigen tests in the inpatient and outpatient setting, considerations for initiating steroids and withholding macrolides, and when to use short antibiotic durations. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/. Visit our website! https://breakpoints-sidp.org/ References: Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. PMID: 31573350; PMCID: PMC6812437. Chaudhuri D, Nei AM, Rochwerg B, Balk RA, Asehnoune K, Cadena R, Carcillo JA, Correa R, Drover K, Esper AM, Gershengorn HB, Hammond NE, Jayaprakash N, Menon K, Nazer L, Pitre T, Qasim ZA, Russell JA, Santos AP, Sarwal A, Spencer-Segal J, Tilouche N, Annane D, Pastores SM. 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia. Crit Care Med. 2024 May 1;52(5):e219-e233. doi: 10.1097/CCM.0000000000006172. Epub 2024 Jan 19. PMID: 38240492. Odeyemi Y, Tekin A, Schanz C, Schreier D, Cole K, Gajic O, Barreto E. Comparative effectiveness of azithromycin versus doxycycline in hospitalized patients with community acquired pneumonia treated with beta-lactams: A multicenter matched cohort study. Clin Infect Dis. 2025 May 16:ciaf252. doi: 10.1093/cid/ciaf252. Epub ahead of print. PMID: 40378193. Butler AM, Nickel KB, Olsen MA, Sahrmann JM, Colvin R, Neuner E, O'Neil CA, Fraser VJ, Durkin MJ. Comparative safety of different antibiotic regimens for the treatment of outpatient community-acquired pneumonia among otherwise healthy adults. Clin Infect Dis. 2024 Oct 23:ciae519. doi: 10.1093/cid/ciae519. Epub ahead of print. PMID: 39442057; PMCID: PMC12355227. Furukawa Y, Luo Y, Funada S, Onishi A, Ostinelli E, Hamza T, Furukawa TA, Kataoka Y. Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. BMJ Open. 2023 Mar 22;13(3):e061023. doi: 10.1136/bmjopen-2022-061023. PMID: 36948555; PMCID: PMC10040075 Schober T, Wong K, DeLisle G, et al. Clinical outcomes of rapid respiratory virus testing in emergency departments. JAMA Intern Med. 2024;184(5):528-536. Clark T, Lindsley K, Wigmosta T, et al. Rapid multiplex PCR for respiratory viruses reduces time to result and improves clinical care: results of a systematic review and meta-analysis. J Infect. 2023;86(5):462-475. May L, Robbins EM, Canchola JA, Chugh K, Tran NK. A study to assess the impact of the cobas point-of-care RT-PCR assay (SARS-CoV-2 and Influenza A/B) on patient clinical management in the emergency department of the University of California at David Medical Center. J Clin Virol. 2023:168:105597. Cartuliares MB, Rosenvinge FS, Mogensen CB, Skovsted TA, Andersen SL, Østergaard C, et al. Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: a multicentre randomised controlled trial. PLoS Med. 2023;20:e1004314. doi: 10.1371/ journal.pmed.1004314. Vaughn VM, Dickson RP, Horowitz JK, Flanders SA. Community-acquired pneumonia: a review. JAMA. 2024;332(15):1282-1295. Davis MR, McCreary EK, Trzebucki AM. Things we do for no reason – ordering Streptococcus pneumoniae urinary antigen in patients with community-acquired pneumonia. Open Forum Infect Dis. 2024;11(3):ofae089. Centers for Disease Control and Prevention. Laboratory Testing for Legionella. Updated June 9, 2025. Accessed July 13, 2025. https://www.cdc.gov/legionella/php/laboratories/index.html. Jain S, Self WH, Wunderink RG. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427. Kamat IS, Ramachandram V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538-542. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single blinded intervention trial. Lancet. 2004;363:600–7. doi: 10.1016/S0140- 6736(04)15591-8. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302:1059–66. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalci- € tonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Datab System Rev. 2017;10(10):CD007498. doi: 10.1002/14651858. cd007498.pub2. Huang DT, Yealy DM, Filbin MR, Brown AM, Chang C-CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower Respiratory tract infection. New Engl J Med. 2018;379:236–49. doi: 10.1056/NEJMoa1802670. Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;389(19):1623-1634. doi:10.1056/NEJMoa2215145. Gupta AB, Flanders SA, Petty LA, et al. Inappropriate diagnosis of pneumonia among hospitalized adults. JAMA Intern Med. 2024;184(5):548-556. Jones BE, Chapman AB, Ying J, et al. Diagnostic Discordance, Uncertainty, and Treatment Ambiguity in Community-Acquired Pneumonia: A National Cohort Study of 115 U.S. Veterans Affairs Hospitals. Ann Intern Med. 2024;177(9):1179-1189. doi:10.7326/M23-2505. Hartlage W, Imlay H, Spivak ES. The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. Antimicrob Steward Healthc Epidemiol. 2024;4(1):e214. doi:10.1017/ash.2024.453. Dinh A, Barbier F, Bedos JP, et al. Update of guidelines for management of community acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF). Endorsed by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF); endorsed by the French Intensive Care Society (SRLF), the French Microbiology Society (SFM), the French Radiology Society (SFR), and the French Emergency Society (SFMU). Respir Med and Res. 2025. El Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355. doi:10.1136/bmj.332.7554.1355. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia: a randomized, non-inferiority trial. Lancet. 2021;397(10280):1195-1203.
On episode #87 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 7/31/25 – 8/18/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged ≥50 years (CID) Bacterial Dalbavancin for Treatment of Staphylococcus aureus Bacteremia (JAMA) Propensity-Matched Comparison of Timely vs. Delayed Antibiotic Therapy in Stenotrophomonas maltophilia Pneumoni (OFID) The proportion of Treponema pallidum PCR-positive primary syphilis infections which are seronegative for syphilis (OFID) Cefixime versus benzathine penicillin G for the treatment of early syphilis (Journal of Antimicrobial Chemotherapy) Dalbavancin for Treatment of Staphylococcus aureus Bacteremia (JAMA) Fungal The Last of US Season 2 (YouTube) Parasitic Increasing Length of the Babesia Season in New England in the Climate Change Era (OFID) Ivermectin to Control Malaria (NEJM) Miscellaneous ACIP Recommendations Summary (CDC: Influenza) Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score (JID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.
Are germs truly the villains of human health—or have we misunderstood the body's healing process from the very beginning? In this eye-opening episode of the Know Better | Do Better Podcast, Autumn sits down with Liev Dalton, founder of Beyond Terrain, to dismantle mainstream medical myths and reveal the truth behind the terrain paradigm. From pleomorphism and the flaws of PCR testing to ancestral wisdom and the body's natural detox processes, Liev uncovers why germ theory may be the greatest medical misdirection of our time—and how reclaiming your health starts with honoring your body, not fearing it. If you've ever questioned the medical system, wondered why symptoms keep coming back, or felt drawn to holistic, root-cause healing, this conversation will challenge everything you thought you knew about illness, microbes, and healing.
Dean's Chat hosts, Drs. Jeffrey Jensen and Johanna Richey, welcome Dr. Joseph Coppola to the podcast! Dr. Coppola is a yound practitioner in Massachusetts, practicing in Community Health Centers in Lynn and Peabody. A fantastic discussion on underserved communities, the medical challenges, the creative ways care can be delivered, and the compassion and empathy he has for his patients. Joseph has been in education since 2012, teaching within the Boston Public Health Commission/Boston University School of Medicine. He taught Anatomy, Physiology, and Biology to high school students. His life long passion for teaching is evident. A graduate of the New York College of Podiatric Medicine in 2020, Dr. Coppola did his 3 year residency training in Podiatric Medicine and Surgery at the Metrowest Medical Center in Framingham, MA. We had a chance to talk about our Dean's Chat sponsor, Bako Diagnostics, as Dr. Coppola participated in the Bako Diagnostics Mini-Fellowship in April 2023. We discussed the intensive Dermatopathology rotation that focuses on the principles of Podiatric Dermatology. He learned different biopsy techniques, utilization of instruments with exposure to specialized testing such as ENFD, immunohistochemistry, mass spectrometry, and real time PCR interpretations of complex cases from the lower extremity. Enjoy!
© 2020-2025 Ivy Podcast Discovery LLC
